# Diabetes Research Hub — Monitor Report
**Run date:** 2026-09-28 (automated Cowork review — no files modified)

---

## File System Status

| File | Last modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-09-27 | 1 day | 🟢 Fresh — **local pipeline resumed after 72 days stalled** (see below) |
| `clinical_trials_latest.json` | 2026-09-27 | 1 day | 🟢 Fresh — finally promoted from the 72-day-old July snapshot |
| `clinical_trials_summary.md` | 2026-09-27 | 1 day | 🟢 Fresh (900 total trials) |
| `pubmed_recent_latest.json` | 2026-09-26 | 2 days | 🟢 Fresh |
| `literature_gap_report.md` | 2026-09-27 | 1 day | 🟢 Fresh (regenerated, same underlying data) |
| `literature_gap_data.json` | 2026-09-19 | 9 days | 🟢 OK — approaching the 14-day refresh threshold |
| `Diabetes_Research_Tracker.xlsx` (master tracker) | 2026-07-17 | **73 days** | 🔴 Still STALE — not touched by yesterday's pipeline fix |

**Resolved since yesterday's report:** Yesterday (2026-09-27 run) flagged a 72-day local-pipeline stall as the top issue — `hub_monitor.py` and `baseline_clinical_trials.py` hadn't run since 2026-07-17. That was fixed the same day: commit `e237eec` ("refresh 72-day-stale clinical trial + hub monitor data") re-ran both scripts. `clinical_trials_latest.json` is now current (900 trials, generated 2026-09-27) and `hub_monitor_report.md` ran its first scan since July. **The Excel tracker was not part of that fix and remains 73 days stale** — worth confirming whether it's still wired into the refresh routine.

**Git status — now the top open issue:** local `main` is **125 commits ahead of `origin/main`**, which has been frozen at 2026-04-20 (over 5 months). This has been flagged and escalated in the repo's own commit log on at least four separate days running (09-16, 09-24, 09-25, 09-26 — each says some version of "push blocker re-verified unchanged, escalated to user") with no push having happened. A fabricated-figure correction (belatacept graft-survival claim) is among the unpushed commits and is still live on the published site. This review did not attempt the push — it requires credentials this review has no way to supply, and publishing is outside an unattended review's remit — but the volume of unpushed history keeps growing and repeated escalation hasn't moved it.

Minor: `Platform_Audit_Report.docx` shows as modified-but-uncommitted, and `Platform_Audit_Report_2026-09-20.docx` is untracked. Not urgent, just noted for cleanliness.

---

## Clinical Trial Changes
*(`clinical_trials_latest.json`, generated 2026-09-27, 900 total trials — first refresh since July)*

**Status changes since the 2026-09-06 snapshot (11 total, most notable):**
- **NOT_YET_RECRUITING → RECRUITING:** CagriSema dose-finding weight/glucose study (NCT07282613, Novo Nordisk); Teplizumab-vs-ATG platform trial to delay Stage 3 T1D (NCT07216391); two UBT251 Phase III T2D studies (NCT07653477, NCT07659574); AZD6234 adjunct-to-incretin studies (NCT07776509, NCT07784270)
- **RECRUITING → ACTIVE_NOT_RECRUITING (enrollment closed):** AIDANET automated insulin delivery trial (NCT07039617); Obicetrapib/Ezetimibe combination study (NCT07219602)
- New trials: 15 | Removed: 9 | **New results postings in this diff: 0**

**Phase 3 RECRUITING trials from tracked organizations (62 Phase 3 RECRUITING total):**
- **Vertex:** 2 — both VX-880 pivotal studies (NCT04786262, NCT06832410), unchanged
- **Eli Lilly:** 4 — Baricitinib BARICADE-DELAY (NCT07222137) and pediatric beta-cell-preservation (NCT07222332); Orforglipron Ramadan-fasting study (NCT07613307); Dulaglutide pediatric dosing (NCT06739122)
- **Novo Nordisk:** 3 — CagriSema dose-finding (NCT07564414); AMBITION 7/zenagamtide (NCT07797335); CagriSema weight/glucose (NCT07282613)
- **Sana Biotechnology:** 0 — still no registered trials (SC451 remains pre-registration per `Research_Findings_Summary.md`)

**New results posting worth a look:** **NCT06045221 — Orforglipron head-to-head vs. Semaglutide in T2D on metformin** (Eli Lilly, Phase 3, N=1,698) posted results **2026-09-15** — this is new since yesterday's report, which only had the 09-04 orforglipron/obesity posting (NCT05872620) on file. Head-to-head data against semaglutide is directly relevant to the orforglipron key-therapy track.

**Zimislecel/VX-880:** still 0 PubMed hits in the last 30 days and no new results postings; both Phase 3 trials remain RECRUITING, unchanged.

---

## PubMed Highlights
*(`pubmed_recent_latest.json`, generated 2026-09-26, 155 unique papers across 16 domains — unchanged from yesterday's report, no newer PubMed pull since)*

**Cross-domain papers (8 new in the 09-23→09-26 window, per `hub_monitor_report.md`'s own diff):**
- [42774718] DNA methylation profiling in diabetic nephropathy — Epigenetics × Complications
- [42783495] MASLD in childhood, disease heterogeneity — Biomarker × Microbiome × Multi-Omics
- [42785112] Evoke(+) semaglutide trials for early Alzheimer's — GLP-1 × Biomarker
- [42787243] AI-driven diabetic retinopathy mapping — AI/ML × Multi-Omics
- [42787324] Inflammatory mechanisms of β-cell dysfunction — Gene Therapy × dapagliflozin
- 3 more microbiome/multi-omics crossovers, none individually urgent (full list in the data file)

**Key-therapy 30-day publication counts:** dapagliflozin 46, orforglipron 13, retatrutide 12, icodec 8, teplizumab 6, CagriSema 4, baricitinib 2, **zimislecel 0** — same pattern as yesterday, still no PubMed activity at all on Vertex's lead cell-therapy candidate.

---

## Gap Analysis Summary
*(`literature_gap_report.md`, regenerated 2026-09-27 08:19 from data generated 2026-09-19 — unchanged rankings from yesterday)*

**Top 5 "meaningful" gaps (Gap Score, all BRONZE — single-source, need expert confirmation):**
1. Beta Cell Regen × Health Equity — 100.0 (0 joint pubs)
2. Insulin Resistance × Islet Transplant — 100.0 (1 joint pub)
3. Islet Transplant × Drug Repurposing — 100.0 (0 joint pubs; re-verified 2026-09-06)
4. Islet Transplant × Health Equity — 100.0 (0 joint pubs)
5. Gene Therapy × LADA — 100.0 (0 joint pubs)

No change from yesterday's rankings — underlying gap data is 9 days old (still under the 14-day threshold, but getting close). Islet Transplant × Drug Repurposing remains the strongest candidate for immediate computational work per Tier 1 alignment (Drug Repurposing Computational Screening, 18/20; Health Equity, 17/20).

---

## Breaking News (web search)

**FDA approved finerenone (Kerendia) for CKD associated with Type 1 diabetes on 2026-09-17** (11 days ago — outside the strict 7-day window but not yet reflected anywhere in this hub, so flagging it). Based on the Phase III **FINE-ONE** trial (242 participants, 80+ sites, 9 countries): finerenone + standard of care reduced UACR by 25% vs. placebo at 6 months (22% at month 3, 28% at month 6), with 68.1% of finerenone patients reaching ≥30% UACR reduction vs. 46.6% on placebo. Bayer describes this as the first new FDA-approved treatment for CKD in T1D in over 30 years — roughly 30% of people with T1D develop CKD. This sits squarely in "Diabetes Complications" territory this hub already tracks and isn't yet a tracked key-therapy or noted anywhere in `Research_Findings_Summary.md`.

No other Phase 3 result or FDA action since the 2026-09-24 Onswik approval (already logged in yesterday's report) cleared the bar for "genuinely significant."

---

## Recommended Actions

1. **Push the 125 unpushed commits** (`git push origin main`) — flagged and escalated on at least four separate automated runs over the past two weeks (09-16, 09-24, 09-25, 09-26) with no action taken; origin/main is now over 5 months stale and a fabricated-figure correction is still live on the published site because of it. This remains outside what an unattended review can do unilaterally.
2. **Add finerenone/Kerendia to the tracked research base** — new FDA approval (2026-09-17) for CKD in T1D, described as the first in 30+ years for this population; not yet reflected in `Research_Findings_Summary.md` or the key-therapy list.
3. **Review the orforglipron-vs-semaglutide head-to-head results** (NCT06045221, posted 2026-09-15, N=1,698) for the Research Findings Summary — new since yesterday's pull.
4. **Confirm the Excel tracker (`Diabetes_Research_Tracker.xlsx`) is still wired into the refresh routine** — it stayed at 73 days stale even though yesterday's fix refreshed the clinical trials data and hub monitor.
5. Re-run `project1_literature_gap_analysis.py` in the next few days — data will cross the 14-day staleness threshold around 2026-10-03.
6. Clean up the uncommitted `Platform_Audit_Report.docx` change and untracked `Platform_Audit_Report_2026-09-20.docx` when convenient (low priority).

---
*Generated by automated Cowork review. No existing files were modified. All data read from `Analysis/Results/`, `RESEARCH_DOCTRINE.md`, git history, and two web search passes.*
